We would love to hear your thoughts about our site and services, please take our survey here.
I think we need DHSE approval fast as we need to look for markets abroad can't rely on UK gov to give us any orders conditionally with MHRA approval, I am amazed there are other private companies already selling test kits, what did ODX miss are we too late in the game really hope there is, some good news on Monday update, so much good news to come but lack of orders or no sign of any contracts we do need to sell abroad
Jollygoodya
Look into companies that manufacture genetic sequencing machines as this is the next big boom in America as life insurances over there will need these tests done by individual forcdting if they are vulnerable to any genetic disease diagnosis for thier insurance premiums
Sorry off topic US stocks
If any interests look out for CODX on NASDAQ
PRODUCTS
Co-Diagnostics offers a range of products and services to suit the needs of diagnostics laboratories, research institutions, and enterprises across the globe that rely on PCR technology. Explore how Co-Diagnostics can help you save money through the application of more efficient, higher-performance molecular diagnostics technology.
APPLICATIONS
Co-Diagnostics was founded with a simple but ambitious goal: to bring high-quality molecular diagnostics for infectious diseases to areas and populations of the world that need them most. Since that time, Co-Diagnostics researchers have developed additional applications far beyond the detection of infectious diseases. Click below to learn more about the many applications of our technology.
TECHNOLOGY
Co-Diagnostics owns all the technology on which its products are designed. We use unique, cutting-edge and patent-protected products for the molecular diagnostics market, which allows for more affordable testing, research, and design solutions. Learn more about our patented CoPrimers™, and the performance and cost-saving advantages of the Co-Diagnostics platform
I have a feeling covid stocks back on rebound as there seems to be more delays on Vaccine and doubts about accuracy
Has anyone heard of Good Law project has initiated legal action against UK Gov for involvement with UK RTC Tests
So let's have that £1 a share at Christmas
Still very cheap to top up facts are clear now
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/07f76b06-73db-4647-97b6-ef0a9a58626d
The UK government is preparing to make nearly £43bn available to companies that can help deliver on its mass Covid-19 testing vision, which aims to roll out rapid turnround tests across the country.
Private and public sector organisations are being invited to apply for three tenders for the supply of new testing technologies as part of prime minister Boris Johnson’s so-called “Project Moonshot” testing programme.
It is anticipated that hundreds of companies will apply to supply products and services to the government as part of the open procurement process.
One tender worth £22bn, released by Public Health England last week, is open to companies that make different testing equipment, including medical devices and “a range of clinical laboratory diagnostic testing services”. It will last for two years, with the option to extend for two more.
Another tender notice released by NHS Supply Chain — which manages the sourcing, delivery and supply of healthcare products — covers the provision of so-called point-of-care tests and diagnostics equipment. The value of the tender has been lifted from £5bn to £20bn “due to the pandemic situation resulting in an immediate overall increased spend in support of [the] Covid-19 testing programme”.
Coronavirus
Oxford Covid vaccine hit 90% success rate thanks to dosing error
Participants given first shot at half strength by mistake were found to be better protected
Coronavirus – latest updates
See all our coronavirus coverage
Jessica Murray and agency
Mon 23 Nov 2020 18.24 EST
Share on FacebookShare on TwitterShare via Email
The Oxford University and AstraZeneca vaccine trials reached 90% efficacy by accident thanks to the “serendipity” of an error that led to some participants receiving half doses, it has emerged.
On Monday scientists revealed that the Oxford vaccine had an overall efficacy of 70%, but could be around 90% effective when administered as a half dose followed by a full dose a month later.
“The reason we had the half dose is serendipity,” said Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca.
When university researchers were distributing the vaccine at the end of April, around the start of Oxford and AstraZeneca’s partnership, they noticed expected side effects such as fatigue, headaches or arm aches were milder than expected.
“So we went back and checked … and we found out that they had underpredicted the dose of the vaccine by half,” said Pangalos.
Instead of restarting the trial, he said researchers decided to continue with the half dose and administer the full dose booster shot at the scheduled time.
About 3,000 people were given the half dose and then a full dose four weeks later, with data showing 90% were protected. In the larger group, who were given two full doses also four weeks apart, efficacy was 62%.
Vaccine results bring us a step closer to ending Covid, says Oxford scientist
Scientists said they still could not fully explain why the half dose gave better protection, but said it may be that it triggers the immune system differently.
Prof Sarah Gilbert from Oxford University, who led the research, said: “It could be that by giving a small amount of the vaccine to start with and following up with a big amount, that’s a better way of kicking the immune system into action and giving us the strongest immune response and the most effective immune response.”
Prof Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the trial, added: “What we don’t know at this moment is whether that difference is in the quality or the quantity of immune response. And that’s something we’re going to be digging into over the next weeks.”
The vaccine still needs to be approved by the Medicines and Healthcare products Regulatory Agency, but could be made available in the coming weeks if given the go-ahead
Wow did not expect drop to this level but fear it nay test 43p trend line before uptick if there is any good news on 30th Nov, I'm still holding average at 67p ouch, one thing I don't get is if ODX are manufacturing these tests then surely they know its a real deal otherwise why take risk in increasing production capacity unless they got it all wrong
Just my thought
https://www.tradingview.com/x/5mFyEfYg/
Without any covid play, ODX, own its own where does it stand I am sure thier other products Colin highlighted in his presentation that are transformal for ODX going forward capable of achieving near 50 million revenue and most have 70 to 75% profit margin that will add value to sp in long run, but it just means money invested here depending on average sp it may take long time to break even or in profit unless we do go ahead with Covid play and gov contract but at the moment it's just speculation nothing concrete until we see the orders, also they waiting on MHRA approval and Mologic tech transfer and DHSC so we can sell Tests abroad, let's hope there is some development on this on 30th nov update some progress atleast
Are we too late in the game of testing as we are not ready to sell a product yet while testing tenders are on the bid with other players who are already selling it , I am hoping we are ready somewhat by middle of December or xmass time
this is getting bit frustrating so much potential here and more testing planned but no orders however if CK is manufacturing the tests everyday he must be quite sure of these orders coming their way once all the approvals in place ,its a hard share to hold at the moment when everything else is going up in regards to Vaccine news ,I would have thought this would have gone up hand in hand , I will hold as I do believe out time will come soon SP will look a lot different in couple of months time more to upside
we should not only depend on UK gov to hand out these TEST contracts but we need to look to promote globally ,delays with MHRA approval is causing issues with Gov contract
The government added that it has already secured access to to 350m vaccine doses by putting in advance orders for several that are in development.
Ministers have spread orders across six potential vaccines that use a variety of methods, stressing that vaccination across the population will not be achieved by a “one size fits all method”
What I fail to understand is that why gov is not ordering twice as amount of Tests to go with hand in hand with Vaccine roll out
I'm not trying to deramp as I am invested here
Has AZ got thier own Tests for thier Vaccine?
What is the end game here can this, do £2 a share upto 400 million market cap?
Hold on to your shares Dec could be fireworks.